Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 283

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Bone and Joint Infections

Saavedra-Lozano, Jesús, Falup-Pecurariu, Oana, Faust, Saul N., Girschick, Hermann, Hartwig, Nico, Kaplan, Sheldon, Lorrot, Mathie, Mantadakis, Elpis, Peltola, Heikki, Rojo, Pablo, Zaoutis, Theoklis, LeMair, Anton·2017·Pediatric Infectious Disease Journal

Abstract

1. INTRODUCTION The European Society for Paediatric Infectious Diseases (ESPID) Bone and Joint Infection Guidelines (ESPID Guidelines) are intended for use by health providers who take care of children with bone and joint infection (BJI). Although BJI can include a diverse range of presentations, these guidelines will focus on “acute, hematogenous BJI in children,” with an emphasis on bacterial infections. ESPID Guidelines are consensus-based practice recommendations developed in a systematic manner that aim to be clear, valid and reliable, and presented with clinical applicability. Because evidence from large randomized controlled trials is rare or lacking, practice statements and recommendations provided here frequently reflect our expert consensus process based on best current practice. Although these guidelines include evidence-based and opinion-based recommendations for the diagnosis and management of children with BJI, these guidelines may not provide the best clinical solution and are not intended to serve as a substitute for the clinical judgment of physicians in individual cases or to establish a protocol valid for all children with these infections. Consequently, they do not represent the “only” appropriate approach for children with this kind of infection. We kindly refer to the full version available online (Supplemental Digital Content, https://links.lww.com/INF/C729) for more information on sources used, literature search strategies, guideline development methodology and the ESPID Review Team. The authors of these ESPID Guidelines have made considerable efforts to ensure that the information upon which they are based is accurate and up-to-date. Users of these guidelines are strongly recommended to confirm that the information contained within them, especially drug doses, is correct by way of independent sources. ESPID and the authors of these guidelines accept no responsibility for any inaccuracies, information perceived as misleading or the outcome of any treatment regimen detailed in the guidelines. 2. SUMMARY OF BJI RECOMMENDATIONS There is a paucity of clinical trial or prospective cohort study data to inform the diagnosis and management of BJI in children. Most data are derived from retrospective, observational studies of variable quality. Therefore, ESPID decided to apply a simple grading of the practice statements in this guideline (see notes below). BJI more frequently affects children younger than 5 years of age, and the infection more often involves joints and bones of the lower extremities (IIA). Staphylococcus aureus is the most prevalent microorganism involved in BJI in children at all ages. In addition, Kingella kingae is a common causative pathogen in children <5 years old in some regions (IIA). C-reactive protein (CRP) and erythrocyte sedimentation rate for the diagnosis of BJI have a high sensitivity, which is slightly increased by combining the 2 tests, whereas the specificity is low (IIB). Ultrasound (US) has a high sensitivity for the diagnosis of septic arthritis (SA), whereas magnetic resonance imaging (MRI) is the most reliable imaging study for the diagnosis of BJI overall (IIA). The isolation of a microorganism from the bone, joint or blood with a clinical or radiologic syndrome compatible with BJI is the gold standard for diagnosis in children (IIA). Empirical antibiotic therapy should be started as soon as possible after collecting appropriate samples for microbiologic analysis upon suspecting BJI in children (IIA). Empirical therapy should include an antibiotic with appropriate coverage against methicillin-sensitive S. aureus (MSSA) and against methicillin-resistant S. aureus (MRSA) in geographical areas with more than 10%–15% prevalence of this bacterium (IIA). Empirical therapy in young children needs to include appropriate coverage for K. kingae in relevant areas (IIA). First-generation cephalosporins, anti-staphylococcal penicillins (ASPs) and clindamycin are the antibiotics most studied in BJI in children (IIA). If MRSA infection is suspected and the patient is not critically ill, empirical therapy should include clindamycin if the rate of clindamycin-resistant S. aureus is less than 10%–15%. A glycopeptide or other appropriate antibiotic for MRSA, such as linezolid, should be included if local clindamycin-resistant MRSA rates are high (IIIB). SA in children should be treated with joint drainage by arthrocentesis, arthrotomy or arthroscopy, depending on the preference and experience of the treating clinicians and surgeons. Arthrocentesis may be appropriate as the only invasive procedure in most uncomplicated cases of SA in children (IIB). Short intravenous (IV) therapy followed by oral therapy is appropriate in the majority of children with uncomplicated BJI based on absence of complications and favorable outcome (IA). Follow-up oral antibiotic therapy should be guided by the antibiotic susceptibilities of the bacteria if isolated; if susceptible, the antibioti

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/inf.0000000000001635

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 283

Metadata

Authors
Saavedra-Lozano, J., Falup-Pecurariu, O., Faust, S. N., Girschick, H., Hartwig, N., Kaplan, S., Lorrot, M., Mantadakis, E., Peltola, H., Rojo, P., Zaoutis, T., & LeMair, A.
Venue
Pediatric Infectious Disease Journal
Published
2017-08
Volume
36
Issue
8
Pages
788-799
ISSN
0891-3668 (ISSN-L)
OpenAlex
W1874084111
Cited by
283
References
47
FWCI
14.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bone and Joint Infections. https://app.cochat.ai/papers/10.1097/inf.0000000000001635
The paper
Saavedra-Lozano, J., Falup-Pecurariu, O., Faust, S. N., Girschick, H., Hartwig, N., Kaplan, S., Lorrot, M., Mantadakis, E., Peltola, H., Rojo, P., Zaoutis, T., & LeMair, A. (2017). Bone and Joint Infections. Pediatric Infectious Disease Journal. https://doi.org/10.1097/inf.0000000000001635

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.